Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X (formerly Twitter) and LinkedIn.WALTHAM, Mass., Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on novel mechanisms in oncology at the Citi 2024 Global Healthcare Conference on Thursday, December 5, 2024 at 11:00 a.m. ET.
马萨诸塞州沃尔瑟姆，2024年11月27日 /PRNewswire/ -- syndax pharmaceuticals（纳斯达克：SNDX），是一家开发创新癌症疗法管线的商业阶段生物制药公司，今天宣布，syndax的首席执行官Michael A. Metzger将于2024年12月5日（星期四）上午11:00参与在花旗2024全球医疗保健大会上关于肿瘤学中新机制的圆桌讨论。
A live webcast of the panel can be accessed from the Investor section of the Company's website at , where a replay will also be available for a limited time.
可通过公司网站的投资者部分访问该小组的实时网络广播，回放也将在有限的时间内提供。
About Syndax
关于Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X (formerly Twitter) and LinkedIn.
syndax pharmaceuticals是一家商业阶段的生物制药公司，正在开发创新的癌症治疗药物。公司的管线重点包括Revuforj（revumenib），这是一种FDA批准的menin抑制剂，以及Niktimvo（axatilimab-csfr），这是一种FDA批准的单克隆抗体，能阻断集落刺激因子1（CSF-1）受体。凭借我们对重新构想癌症护理的承诺，Syndax正致力于释放其管线的全部潜力，并在治疗的各个环节进行多项临床试验。欲了解更多信息，请访问或在X（前称Twitter）和LinkedIn上关注公司。
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
syndax pharmaceuticals 联系方式
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
电话 781.684.9827
SNDX-G
SNDX-G
SOURCE Syndax Pharmaceuticals, Inc.
消息来源：Syndax Pharmaceuticals，Inc。
